Table 2.

Univariate Analysis for Identifying the Predictors of Invasive HvKP Infection

Variables	Invasive HvKP (43)	Non-Invasive HvKP (38)	P-value
Demographics
Male sex	30 (69.76)	27 (71.05)	0.229
Age, >60 years	17 (39.53)	20 (52.63)	0.238
Length of hospital stay at the time of infection (day)	18 (18.00)	22 (35.75)	0.424
Underlying disease
Hypertension	5 (11.63)	20 (52.63)	<0.001
Urinary tract infection	11 (25.58)	10 (26.32)	0.94
Lung disease	15 (34.88)	23 (60.52)	0.021
Smoking and drinking history	4 (9.3)	5 (13.16)	0.728
Neurologic disease	3 (6.98)	17 (44.74)	<0.001
Cardiovascular disease	1 (2.32)	10 (26.32)	0.002
Agranulocytosis	1 (2.32)	0	1.0
Splenectomy	2 (4.65)	0	0.496
Peritonitis	6 (13.95)	1 (2.63)	0.114
Liver disease	22 (51.16)	5 (13.16)	<0.001
Diabetes mellitus	21 (48.83)	10 (26.32)	0.037
Tumor disease	10 (23.25)	6 (15.79)	0.4
Invasive procedures
Mechanical ventilation	10 (23.25)	16 (42.11)	0.07
Catheter drainage	24 (55.81)	4 (10.52)	<0.001
Thoracentesis	10 (23.25)	9 (23.68)	0.964
Lumbar puncture	3 (6.97)	13 (30.23)	0.002
Tracheotomy	10 (23.25)	12 (31.58)	0.401
Therapy
Hormone therapy	7 (16.27)	2 (5.26)	0.162
Monotherapy	9 (20.93)	5 (13.15)	0.356
Combination therapy	34 (79)	33 (86.84)	0.356
Antibiotic therapy combined with puncture drainage	22 (50%)	2 (4.4%)	<0.001
Antibiotic therapy before cultivation	4 (9.3)	0	0.119
Antibiotics
Enzyme inhibitor complex	14	18	0.174
Quinolones	6	6	0.816
Carbapenems	17	3	0.001
Cephalosporins	6	5	0.917
Prognosis
Death	3 (6.97)	4 (10.52)	0.701
Improved	33 (76.74)	26 (68.42)	0.401
Abandoned treatment	7 (16.28)	8 (21.05)	0.581
Capsular serotype
K1	18 (41.86)	4 (10.52)	0.002
K2	13 (30.23)	11 (28.95)	0.899
K57	10 (23.25)	10 (26.32)	0.75
MLST
ST23	15 (34.88)	5 (13.16)	0.04
ST86	5 (11.63)	6 (15.79)	0.585
ST218	5 (11.63)	4 (10.52)	1.0
Virulence positive (rmpA/rmpA2/iroN/iutA)
Positive for the 4 virulence genes	38 (88.37)	31 (81.58)	0.39